Tag Archives: patent

IP in Latin America: Growing Recognition of the Importance of IP to Innovation

Photo by Márcio Cabral de Moura

The Inter-American Dialogue’s daily Latin America Advisor recently asked the question “How seriously do Latin American countries protect IP rights?”  The editors asked various stakeholders about the U.S. Trade Representative’s Special 301 Report and its evaluation of Latin America’s protection of IP rights.  BIO’s Director for International Affairs, Meredith Fensom, commented on the growth of the innovative biotechnology sectors in Latin America and the critical role intellectual property plays.  ”The presence of more than 60 Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Gene Patents, Angelina Jolie, and Reality

Gene Patents, Angelina Jolie, and Reality

By Dr. Hans Sauer, J.D., Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization  Angelina Jolie recently announced her personal connection with breast cancer and Myriad’s BRCA genetic test.  While Jolie’s post was a commendable personal account of the real world impact of breast cancer and the real world impact of developments in healthcare technology, a few less informed individuals have tried to take advantage of this recent announcement from stardom and spread misinformation.  Let’s Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , ,

Kirtsaeng v. John Wiley & Sons: No Good Deed Goes Unpunished

Supreme Court

The Supreme Court handed Kirtsaeng a victory last week finding his importation and resale of copyrighted books exhausted the copyright under the First Sale Doctrine. In a vain attempt at corporate responsibility, the publishers in this case created two versions of textbooks; a no-frills “Asia edition” to sell at affordable prices to students in less affluent places like Thailand, and a higher quality more expensive version to relatively more affluent students in places like the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Fireside Chat

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and they’re facing the losses of the antidepressant Cymbalta in December of 2013 and the osteoporosis drug Evista in 2014. The loss of protection endangers the company’s ability to profit from the drugs and they could face a $25 billion loss in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Brazil Patent Policy: At a Crossroads

Photo By: DigiDreamGrafix.com

The Government of Brazil approaches the patent policy crossroads with two ministries wanting to move in opposite directions.  In the last few months, both the Brazilian Patent Office (INPI) and the Brazilian Regulatory Authority (ANVISA) issued proposed rules concerning patents and are sifting through public comments to determine how they will deal with biotech patents. A quirk in Brazilian law requires that the health regulatory authority (ANVISA) must provide “prior consent” on the grant of a pharmaceutical patent.  Traditionally, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,